Tempest Therapeutics, Inc. (TPST) Earnings Signals & AI Vibe Check

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Tempest Therapeutics, Inc.'s filing signal turned positive.

Tempest Therapeutics is a clinical-stage biotechnology company focused on developing a diversified portfolio of cell therapy and small molecule product candidates for cancer indications. In February 2026, the company significantly expanded its pipeline by acquiring rights to dual-targeting CAR-T cell therapy product candidates, including TPST-2003 for multiple myeloma, and also advanced its small molecule candidates, amezalpat for hepatocellular carcinoma and TPST-1495 for familial adenomatous polyposis. Tempest aims to address high unmet medical needs by advancing promising clinical-stage candidates through a capital-efficient development strategy, often seeking partner support and external funding. The company's strategy involves parallel development of multiple programs while managing internal cash resources and extending its operational runway.

The company currently generates no revenue from product sales. Future revenue is expected to be driven by the successful development and commercialization of its product candidates, amezalpat and TPST-1495, and its CAR-T cell therapies.